One transgenic strategy (using the S100A8 (MRP8) 5′ flanking region) resulted in myeloid leukemia, while two others (using Fes and Itgam (CD11b) promoters) did not [3], [19], [20]. This evidence concerns the gene S100A8 and myeloid leukemia.